Hydroxychloroquine

Generic Name: Hydroxychloroquine

Brand Names: Plaquenil, Sovuna

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₆ClN_₃O

CAS Number: 118-42-3

Unique Ingredient Identifier: 4QWG6N8QKH

Background: Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.

The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

Hydroxychloroquine was granted FDA approval on 18 April 1955.

A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.

Indication: Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions: Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum

Associated Therapies: -

Clinical Trials

Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients

Phase 2

Conditions: HIV Infections

Interventions: Drug: Placebo
Drug: Hydroxychloroquine

First Posted Date: 2010-02-11

Last Posted Date: 2010-07-30

Lead Sponsor: Medical Research Council

Target Recruit Count: 83

Registration Number: NCT01067417

Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: erlotinib
Drug: hydroxychloroquine

First Posted Date: 2009-12-04

Last Posted Date: 2017-01-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 27

Registration Number: NCT01026844

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

Phase 1

Completed

Conditions: Malignant Solid Tumour

Interventions: Drug: Hydroxychloroquine
Drug: Vorinostat

First Posted Date: 2009-12-02

Last Posted Date: 2023-02-13

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 72

Registration Number: NCT01023737

Locations: 🇺🇸
Cancer Therapy & Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: hydroxychloroquine

First Posted Date: 2009-11-01

Last Posted Date: 2021-09-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 38

Registration Number: NCT01006369

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Cooper Hospital/University Medical Center, Camden, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States

and more 1 locations

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: Hydroxychloroquine

First Posted Date: 2009-09-15

Last Posted Date: 2020-07-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 76

Registration Number: NCT00977470

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 1 locations

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Early Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: hydroxychloroquine

First Posted Date: 2009-08-20

Last Posted Date: 2022-09-07

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 20

Registration Number: NCT00962845

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2009-05-29

Last Posted Date: 2019-04-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT00909831

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients

Completed

Conditions: Sjögren's Syndrome
Xerostomia

Interventions: Drug: Hydroxychloroquine

First Posted Date: 2009-04-01

Last Posted Date: 2009-04-01

Lead Sponsor: Ege University

Target Recruit Count: 30

Registration Number: NCT00873496

Locations: 🇹🇷
Ege University School of Dentistry, Izmir, Bornova, Turkey

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Drug: Hydroxychloroquine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sunitinib Malate

First Posted Date: 2008-12-23

Last Posted Date: 2023-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00813423

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: hydroxychloroquine

First Posted Date: 2008-11-06

Last Posted Date: 2023-08-14

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 11

Registration Number: NCT00786682

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
🇺🇸
Overlook Hospital, Summit, New Jersey, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy